Patients with Lennox-Gastaut syndrome (a severe form of childhood epilepsy) respond very poorly to current treatment options, but GW Pharma's (GWP) drug, Epidiolex, is no ordinary treatment. Its active substance is derived from cannabinoids and it has now proved twice that it can successfully reduce seizure incidence.
IC TIP:
Buy
at
800p
This week GW announced its second positive result from a Lennox-Gastaut phase III trial, which proved that Epidiolex works at both 10mg and 20mg doses. In March the drug was also successful in treating Dravet Syndrome, another strain of epilepsy.